Amgen (AMGN-NASDAQ) posted EPS of $0.90, but $0.71 on GAAP EPS. Revenues were $3.73 Billion versus $3.7 Billion estimates. Revenues are projected for $15.4 to $16 Billion for 2007 and adjusted EPS put for 2007 at $4.30 to $4.50. Estimates for the quarter were $0.94 to $0.95 depending on your consensus, but 2007 estimates are $4.43.
The stock closed down 0.4% at $74.85 and is down almost 2% around $73.50 in the initial reaction. At the mid-point this is only a 17 P/E for 2007, so investors aren’t willing to pay up for Amgen’s earnings based on Congressional scares and potential patent issues in 2008 and beyond. The valuation isn’t the issue here, because this ons has been cheaper than many Big Pharma stocks for a while. Its market cap is $87 Billion.
Amgen is no longer treated like a biotech, it’s treated like a plain Jane drug stock. That might not be fair, but the market sets the rules.
Jon C. Ogg
January 25, 2007
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
